 This is an open-label all people know the identity of the intervention study to assess the antiviral activity, safety, tolerability and pharmacokinetics explores what the body does to the medication of TMC435350 hereafter referred to as TMC435. Approximately 40 participants will be divided in 5 groups as per the genotype 8 participants each group. The study will include a screening phase up to 6 weeks, treatment phase 7 days and a follow-up phase 30-35 days after the last dose of study medication. Safety evaluations will include assessment of adverse events, clinical laboratory tests and cardiovascular safety. 